Holen Sie sich die Stockscreener-App
63.66
0.16%
0.10
Handel nachbörslich:
63.47
-0.19
-0.30%
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback - simplywall.st
Halozyme names David Ramsay as interim CFO By Investing.com - Investing.com India
Halozyme names David Ramsay as interim CFO - Investing.com South Africa
Halozyme Taps David Ramsay as Interim Chief Financial Officer - Contract Pharma
Halozyme Names David Ramsay Interim Chief Financial Officer - TipRanks
Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026 - marketscreener.com
Halozyme (HALO) Appoints David Ramsay as Interim CFO - GuruFocus
Halozyme (HALO) Appoints Interim CFO Amid Search for Permanent E - GuruFocus
Halozyme Appoints David Ramsay as Interim Chief Financial Officer - PR Newswire
Capital Fund Management Boosts Stake in Halozyme Therapeutics - National Today
Capital Fund Management S.A. Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations By Investing.com - Investing.com Nigeria
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations - Investing.com
Insider Selling: Cortney Caudill Unloads $1.96M Of Halozyme Therapeutics Stock - Benzinga
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Halozyme Therapeutics COO Sells $599,000 in Shares - National Today
Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 8,857 Shares - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 20,000 Shares of Stock - MarketBeat
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery By Investing.com - Investing.com Canada
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery - Investing.com
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - GlobeNewswire Inc.
Neo Ivy Capital Management Reduces Stake in Halozyme Therapeutics - National Today
Neo Ivy Capital Management Cuts Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
DLD Asset Management LP Has $2.20 Billion Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Victory Capital Management Trims Halozyme Therapeutics Stake - National Today
Victory Capital Management Inc. Sells 46,430 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment - marketscreener.com
Drug combo for relapsed or refractory myeloma cuts progression or death risk 83% - Stock Titan
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case - ChartMill
Did Record ENHANZE Royalties and New Deals Just Shift Halozyme Therapeutics' (HALO) Investment Narrative? - Sahm
Snyder Capital Management L P Sells 663,853 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Shares Sold by Investment Firm - National Today
Halozyme Therapeutics, Inc. $HALO Shares Sold by GW&K Investment Management LLC - MarketBeat
Cresset Asset Management LLC Reduces Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,393,800.00 in Stock - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock - MarketBeat
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback - Yahoo Finance
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Halozyme Therapeutics (HALO) Valuation Check As Recent Share Pullback Follows Strong Multi Year Returns - Yahoo Finance
Segall Bryant & Hamill LLC Sells 94,261 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Fisher Asset Management Boosts Stake in Halozyme Therapeutics - National Today
Fisher Asset Management LLC Purchases 29,147 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO Earnings History & Surprises | EPS & Revenue Results | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme at TD Cowen Health Care Conference: Strategic Growth Insights - Investing.com
Halozyme Therapeutics (HAM:RV7) Total Operating Expense : €318 Mil (TTM As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Sees Increased Investment from Handelsbanken Fonder AB - National Today
Halozyme Therapeutics (HAM:RV7) Investments And Advances : €0 Mil (As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Stock Holdings Reduced by Rafferty Asset Management - National Today
Halozyme Therapeutics, Inc. $HALO Stock Holdings Lessened by Rafferty Asset Management LLC - MarketBeat
Halozyme Acquisitions And ENHANZE Growth Shape Long Term Valuation Story - Sahm
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unlocking A 21.53% Potential Upside - DirectorsTalk Interviews
Halozyme Therapeutics (HAM:RV7) Ending Cash Position : €117 Mil (As of Dec. 2025) - GuruFocus
Why Halozyme Therapeutics (HALO) Is Up 8.1% After Raising 2026 Revenue Guidance to up to $1.81 Billion - Sahm
Halozyme Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
A Look At Halozyme Therapeutics (HALO) Valuation After Recent Share Price And Licensing Momentum - simplywall.st
Is Halozyme Therapeutics (HALO) a Buy Post Earnings? - Finviz
Artisan Partners Limited Partnership Sells 752,150 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HAM:RV7) Preferred Stock : €0 Mil (As of Dec. 2025) - GuruFocus
12 Cheap Biotech Stocks to Buy Now - Insider Monkey
Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory - Finviz
Halozyme Therapeutics (HAM:RV7) Book Value per Share : €0.35 (As of Dec. 2025) - GuruFocus
Halozyme Therapeutics, Inc. $HALO Position Boosted by Handelsbanken Fonder AB - MarketBeat
Halozyme Therapeutics (HAM:RV7) Additional Paid-In Capital : €10 Mil(As of Dec. 2025) - GuruFocus
Halozyme Therapeutics (HAM:RV7) ROE % Adjusted to Book Value : -1.24% (As of Dec. 2025) - GuruFocus
Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):